中国城乡11市县常见恶性肿瘤发病趋势分析

目的 探讨中国恶性肿瘤发病特点及时间趋势.方法 采用中国城乡11个市县肿瘤登记处的1988-2002年资料进行统计与分析,描述恶性肿瘤发病现状,研究其时间趋势与发病特点.结果 11个市县肿瘤登记处覆盖地区15年内新发恶性肿瘤695 050例,粗发病率为215.50/10万,世界标准人口调整发病率为170.97/10万.主要恶性肿瘤发病率排序依次为肺癌、胃癌、肝癌、食管癌、乳腺癌、结肠癌、直肠癌、胰腺癌、膀胱癌、白血病.16种主要恶性肿瘤占全部的85.56%.1988-2002年恶性肿瘤合并的粗发病率呈较快上升趋势.按部位分析,增幅最大的是前列腺癌(185.48%),其次为胆囊癌、乳腺癌、结肠癌等.发病率下降幅度最大的是宫颈癌(17.00%),其次为食管癌、胃癌、鼻咽癌.结论 中国11个市县1988-2002年恶性肿瘤总的粗发病率呈上升趋势,调整年龄因素后变化不明显.胰腺癌、膀胱癌、白血病已进入前10位,成为常见恶性肿瘤.前列腺癌和胆囊癌发病率虽然较低,但是增长幅度最大.

Study on cancer incidence through the Cancer Registry Program in 11 Cities and Counties, China

Objective Aim of this paper was to explore the trend and characteristics of cancer incidence in 11 areas (5 cities and 6 counties) in China. Methods Data from cancer registries during 1988 to 2002 collected from the 11 cancer registry points were used to analyze the trends and characteristics of cancer incidence rates. Results There were 695 050 newly developed cancer cases in this study. The crude rate of incidence and the world age-adjusted incidence were 215.50/105 and 170.97/105 respectively. The leading cancer sites were lung, stomach, liver, esophagus, breast, colon, rectum, pancreas, bladder and leukemia. The sixteen key cancers accounted for 85.56% of all the cancer cases. The crude incidence rate of all cancers had been significantly increased from 1988 to 2002. Among them, prostate (185.48%) ranked the fastest growing one followed by cancers of the gallbladder, breast, colon, ovarian, lymphoma, bladder, pancreas, rectum, lung, leukemia and liver. The one that had reduced the most was cervix uteri (17.00%), followed by esophagus, stomach and nasopharynx. Conclusion Crude cancer incidence rate increased in the 11 areas in China from 1988 to 2002. The ranking of pancreas cancer, bladder cancer and leukemia came into the top ten. Even though the incidence rates of prostate and gallbladder cancer were relative low but had a fast increase. The results of this study provided a scientific base for the development of a better strategy on cancer prevention and control in China.